BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27039262)

  • 21. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.
    Gros A; Laharanne E; Vergier M; Prochazkova-Carlotti M; Pham-Ledard A; Bandres T; Poglio S; Berhouet S; Vergier B; Vial JP; Chevret E; Beylot-Barry M; Merlio JP
    PLoS One; 2017; 12(3):e0173171. PubMed ID: 28301507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
    Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
    So CC; Wong KF; Siu LL; Kwong YL
    Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
    Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
    Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
    Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities.
    Batista DA; Vonderheid EC; Hawkins A; Morsberger L; Long P; Murphy KM; Griffin CA
    Genes Chromosomes Cancer; 2006 Apr; 45(4):383-91. PubMed ID: 16382449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the novel Sezary lymphoma cell line BKP1.
    Boudjarane J; Essaydi A; Farnault L; Popovici C; Lafage-Pochitaloff M; Beaufils N; Berda-Haddad Y; Lacroix R; Nicolino-Brunet C; Le Treut T; Zattara H; Gabert J; Kahn-Perlès B; Costello R
    Exp Dermatol; 2015 Jan; 24(1):60-2. PubMed ID: 25314094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
    Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
    Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Sézary syndrome].
    Ferreira F; Correia TM; Callabro L; Andrade J
    Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Histoclinical and immunohistochemical diagnosis of cutaneous lymphomas].
    Maryniak RK; Jankowska-Konsur A
    Pol J Pathol; 2011 Dec; 62(4 Suppl 3):s1-23. PubMed ID: 22693733
    [No Abstract]   [Full Text] [Related]  

  • 35. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
    LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
    Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
    Nevet MJ; Zuckerman T; Sahar D; Bergman R
    Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays.
    Caprini E; Cristofoletti C; Arcelli D; Fadda P; Citterich MH; Sampogna F; Magrelli A; Censi F; Torreri P; Frontani M; Scala E; Picchio MC; Temperani P; Monopoli A; Lombardo GA; Taruscio D; Narducci MG; Russo G
    Cancer Res; 2009 Nov; 69(21):8438-46. PubMed ID: 19843862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional Her 2/neu gene copies in patients with Sézary syndrome.
    Utikal J; Poenitz N; Gratchev A; Klemke CD; Nashan D; Tüting T; Goerdt S
    Leuk Res; 2006 Jun; 30(6):755-60. PubMed ID: 16303179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.